Drug Discovery World

NOVEMBER 2, 2023

DenovAI is the second start-up to launch from the global pharma consortium AION Labs – an organisation that aims to improve the drug discovery and development process through the use of AI and other computational technologies. RA: How laborious and expensive are current antibody discovery efforts? KS: In short, incredibly so.

Antibody 83

Antibody Protein Development Drugs 83

Drug Discovery World

JANUARY 16, 2024

Biotech company ExeVir Bio has revealed new data demonstrating that its antibodies are effective in neutralising currently circulating Covid-19 Omicron variants. XVR013m is a heavy chain-only antibody targeting a unique membrane-proximal epitope in the S2 subunit of the spike protein. XVR012 demonstrates an IC50 range of 0.8

Antibody 104

Antibody Protein Vaccination Vaccine 104

Bio Pharma Dive

AUGUST 14, 2023

Elrexfio is the third bispecific antibody cleared to treat the blood cancer, and will compete with other therapies that target the “BCMA” protein on myeloma cells.

FDA Approval 246

FDA Approval Protein Antibody Drugs 246

Bio Pharma Dive

JUNE 16, 2023

The approval of Columvi adds another “bispecific antibody” to the market, highlighting the fast research progress for drugs that target two proteins rather than one.

FDA Approval 171

FDA Approval Drugs Protein Antibody 171

Bio Pharma Dive

JUNE 5, 2023

Results from a “basket” trial of the antibody-drug conjugate show it shrank tumors across a half dozen cancers, suggesting a broader role to targeting the protein HER2.

Drugs 177

Drugs Protein Antibody Trials 177

Drug Discovery World

APRIL 30, 2024

This eBook, sponsored by Thermo Fisher Scientific, explores the impact of monoclonal antibodies (mAbs) on the treatment of cancer, autoimmune and infectious diseases, and inflammatory conditions, as well as the latest clinical research and where the innovation in mAb development might be in the future.

Drugs 52

Drugs Antibody Engineer Protein 52

Bio Pharma Dive

FEBRUARY 15, 2024

Armed with $94 million in funding, the biotech is marrying antibody-drug conjugates with protein degraders to create a new kind of cancer medicine.

Protein 183

Protein Antibody Medicine Drugs 183

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. Financing When it comes to looking to the future in the drug discovery industry, an important question to ask is: Where is the money?

Antibody 98

Antibody Marketing Drugs Licensing 98

Drug Discovery World

MARCH 12, 2024

DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates.

Antibody 81

Antibody FDA Approval Drugs Development 81

Bio Pharma Dive

OCTOBER 26, 2022

The treatment, which will be sold as Tecvayli, is the first bispecific antibody cleared for the disease. It joins a group of medicines on market that target a protein called BCMA.

Protein 284

Protein Antibody Medicine Drugs 284

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 246

Antibody Vaccination Vaccine Dermatology 246

Drug Discovery World

MARCH 4, 2024

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. The post Antibody therapy shows anti-tumour activity in advanced cancer appeared first on Drug Discovery World (DDW).

Antibody 115

Antibody Immune Response Trials Clinical Trials 115

Bio Pharma Dive

OCTOBER 20, 2022

The deal gives AbbVie an experimental medicine for idiopathic pulmonary fibrosis, as well as a platform for designing antibody drugs that can target proteins known as GPCRs.

Protein 321

Protein Antibody Medicine Drugs 321

Drug Discovery World

APRIL 30, 2024

The low toxicity and high specificity of monoclonal antibodies (mAbs) continue to make them an appealing target for clinical research and investment. The post New ebook: Drug discovery and the impact of mAbs appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Drugs Clinical Research Engineer 52

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.

Antibody 147

Antibody Production Protein Regulation 147

Bio Pharma Dive

SEPTEMBER 7, 2023

The alliance, which aims to combine Seagen’s antibody expertise with Nurix’s targeted protein degradation research, comes as the larger biotech awaits its acquisition by Pfizer to close.

Protein 171

Protein Antibody Drugs Research 171

Bio Pharma Dive

MAY 18, 2021

The pharma acquired rights to an experimental antibody medicine that blocks a protein, called TIGIT, that's become a focus for several cancer drugmakers.

Protein 333

Protein Antibody Medicine Drugs 333

Pharmaceutical Technology

APRIL 5, 2023

Under the collaboration, Absci’s generative AI drug creation platform will use M2GEN’s ORIEN AVATAR (AVATAR), a clinical and molecular data set, to speed up the creation of therapies for a range of malignancies and patient profiles.

Development 130

Development Bioinformatics Drugs Immune Response 130

STAT News

DECEMBER 10, 2022

NEW ORLEANS — Researchers had hoped in recent years that a protein called GPRC5D might offer a new way to get the immune system to hunt down and destroy multiple myeloma cells. Now, the results of a Phase 2 study on a bispecific antibody targeting this protein offers confirmation.

Antibody 132

Antibody Protein Trials Research 132

Drug Discovery World

SEPTEMBER 1, 2022

Bio-Rad Laboratories has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. .

Antibody 52

Antibody In-Vitro Development Recombinant Antibody 52

Bio Pharma Dive

OCTOBER 28, 2020

The two Swiss firms will develop protein drugs that are meant to have similar effects as coronavirus antibodies, but would be easier to mass produce.

Development 200

Development Drugs Protein Antibody 200

Roots Analysis

JANUARY 21, 2024

With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. In this context, the role of the linker molecule and the conjugation technology used is pivotal.

Antibody 40

Antibody Recombinant DNA Technology Drugs Marketing 40

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. At the helm of this venture is Dr. Taylor H. How is your lead program differentiated?

Protein 94

Protein Development Clinical Trials Clinical Trials 94

Bio Pharma Dive

JANUARY 17, 2023

The deal gives Leap several early-stage drug candidates, including an antibody targeting the protein Claudin 18.2, which has lately drawn several other biotech companies’ interest.

Protein 194

Protein Antibody Drugs 194

Drug Discovery World

MARCH 8, 2024

The top stories: Antibody therapy shows anti-tumour activity in advanced cancer In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer.

Antibody 52

Antibody Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

JULY 24, 2023

The Defense Advanced Research Projects Agency (DARPA) has announced that Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has been awarded a four-year contract worth up to $18 million to reimagine how to manufacture complex therapeutic proteins.

Protein 52

Protein Manufacturing Gene Sequencing Production 52

Drug Discovery World

OCTOBER 12, 2022

In the Quality by Design (QbD) approach to antibody-based therapeutics development, stability characterisation —the probability of a protein unfolding or denaturing— is performed to ensure that structure and function are preserved throughout development and manufacturing. . Approaches for monoclonal antibody formulation .

Antibody 52

Antibody Development Licensing Licensing 52

pharmaphorum

FEBRUARY 28, 2024

AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Immunotherapeutics.

Protein 104

Protein Antibody Drugs Development 104

Drug Discovery World

DECEMBER 20, 2022

A project creating a new class of therapeutic proteins to modulate cell signalling has been accepted into the BioInnovation Institute (BII) Bio Studio programme. De novo protein design is an exciting area and one that fits perfectly with our strategy to accelerate the commercialisation of state-of-the-art technology.” .

Protein 52

Protein Life Science Antibody Business Development 52

pharmaphorum

MAY 30, 2022

All three of the studies Verma mentioned involved antibody-drug conjugates (ADCs), a treatment modality that’s now about a decade old but still ripe for innovation. “An An antibody-drug conjugate is where you connect and link a chemotherapy to an antibody,” Verma said. The Trojan horse.

Antibody 111

Antibody Drugs Medicine Research 111

Drug Discovery World

JANUARY 10, 2023

For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. All of our antibodies are highly validated using six pillars of validation, meaning that our antibodies do what we say they’ll do.

Antibody 52

Antibody Protein Reagent Scientist 52

Drug Discovery World

APRIL 25, 2024

Xaira is building a platform for drug discovery and development that it hopes will advance multiple drug programmes and unlock biological understanding to inform future discovery. It employs a group of researchers who developed the leading models for protein and antibody design, RFdiffusion and RFantibody, while in Dr Baker’s lab.

Drugs 52

Drugs Protein Antibody Engineer 52

Drug Discovery World

OCTOBER 12, 2022

In the Quality by Design (QbD) approach to antibody-based therapeutics development, stability characterisation —the probability of a protein unfolding or denaturing— is performed to ensure that structure and function are preserved throughout development and manufacturing. . Approaches for monoclonal antibody formulation .

Antibody 52

Antibody Development Licensing Licensing 52

Medical Xpress

FEBRUARY 3, 2023

There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases. A study led by researchers from Karolinska Institutet has now identified a drug candidate for the treatment of fatty liver.

Antibody 75

Antibody Protein Drugs Research 75

Drug Discovery World

MARCH 1, 2023

Antiverse has successfully identified functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity. The company has raised $3 million in funding, which will enable in-house development of the antibodies showing the highest affinity blocking function.

Antibody 52

Antibody Development In-Vivo FDA Approval 52

BioPharma Reporter

OCTOBER 24, 2022

AbbVie will acquire DJS Antibodies Ltd, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins.

Antibody 45

Antibody Protein Medicine Development 45

Drug Discovery World

NOVEMBER 14, 2023

DDW’s Megan Thomas looks at how different diseases will benefit from the success of therapeutic antibodies. Cancer Monoclonal antibodies (mAbs) are a type of targeted drug therapy, and as such are often used to treat cancer. At the time, aducanumab was the first new Alzheimer’s drug in nearly 20 years.

Antibody 59

Antibody Development FDA Approval Trials 59